Alkermes (ALKS) vs Belite Bio (BLTE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Belite Bio (BLTE) has outperformed Alkermes (ALKS) over the past year, gaining 101.7% versus a gain of 33.9%. Alkermes is the larger company by market cap ($6.95 billion vs $6.29 billion), about 1.1 times the size. On valuation, Alkermes trades at a lower forward P/E (22.9x vs 69.1x for Belite Bio).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | BLTE |
|---|---|---|
| Share price | $41.45 | $156.08 |
| Market cap | $6.95B | $6.29B |
| 1-day change | -0.49% | +0.30% |
| YTD return | +48.12% | -2.43% |
| 1-year return | +33.91% | +101.65% |
| 5-year return | +30.87% | — |
| P/E ratio (TTM) | 109.07 | — |
| Forward P/E | 22.92 | 69.06 |
| EPS (TTM) | $0.38 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | — |
| Revenue growth (YoY) | -5.25% | — |
| Net income (latest FY) | $241.66M | $-77.61M |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | — |
| Net margin | 16.37% | — |
| 52-week high | $55.67 | $200.00 |
| 52-week low | $27.00 | $76.50 |
| Distance from 52-week high | -25.55% | -21.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +36.47% | +46.65% |
| Average volume | 1.83M | 182.25K |
| Shares outstanding | 167.76M | 40.27M |
| Employees | 2,050 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed ALKS by 67.7 percentage points over the past year.
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
ALKS vs BLTE FAQ
Which is bigger, Alkermes or Belite Bio?
Alkermes (ALKS) is larger, with a market capitalization of $6.95B compared with $6.29B for Belite Bio (BLTE).
Which stock has performed better over the past year, ALKS or BLTE?
BLTE returned +101.65% over the past 12 months, compared with +33.91% for ALKS (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Belite Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.